Cohort description
| . | Discovery cohort (n = 69) . | Flow cytometry cohort (n = 8, diagnosis) . |
|---|---|---|
| Age, median (range), y | 61 (19-88) | 55 (21-77) |
| Male, % | 48 | 75 |
| Etiology, % | ||
| De novo | 93 | 100 |
| Secondary (MDS or therapy-related) | 7 | 0 |
| Event, %* | 68 | 50 |
| FAB classification, % | ||
| M0 | 4 | 0 |
| M1 | 24 | 13 |
| M2 | 34 | 50 |
| M3 | 1 | 0 |
| M4 | 10 | 0 |
| M5 | 16 | 38 |
| M6 | 1 | 0 |
| M7 | 1 | 0 |
| Unspecified | 7 | 0 |
| Complete remission following induction therapy, % | 83 | 100 |
| Time from diagnosis to event,* median (range), mo | 13 (0-132) | 22 (5-48) |
| ELN 2017 risk class, % | ||
| Favorable | 4 | 13 |
| Intermediate | 45 | 63 |
| Adverse | 19 | 25 |
| Unknown | 32 | 0 |
| Induction treatment, % | ||
| Intensive therapy† | 86 | 88 |
| Cytarabine or azacitidine monotherapy | 4 | 1 |
| No therapy or other therapy | 10 | 0 |
| Allo-HSCT | 36 | 63 |
| . | Discovery cohort (n = 69) . | Flow cytometry cohort (n = 8, diagnosis) . |
|---|---|---|
| Age, median (range), y | 61 (19-88) | 55 (21-77) |
| Male, % | 48 | 75 |
| Etiology, % | ||
| De novo | 93 | 100 |
| Secondary (MDS or therapy-related) | 7 | 0 |
| Event, %* | 68 | 50 |
| FAB classification, % | ||
| M0 | 4 | 0 |
| M1 | 24 | 13 |
| M2 | 34 | 50 |
| M3 | 1 | 0 |
| M4 | 10 | 0 |
| M5 | 16 | 38 |
| M6 | 1 | 0 |
| M7 | 1 | 0 |
| Unspecified | 7 | 0 |
| Complete remission following induction therapy, % | 83 | 100 |
| Time from diagnosis to event,* median (range), mo | 13 (0-132) | 22 (5-48) |
| ELN 2017 risk class, % | ||
| Favorable | 4 | 13 |
| Intermediate | 45 | 63 |
| Adverse | 19 | 25 |
| Unknown | 32 | 0 |
| Induction treatment, % | ||
| Intensive therapy† | 86 | 88 |
| Cytarabine or azacitidine monotherapy | 4 | 1 |
| No therapy or other therapy | 10 | 0 |
| Allo-HSCT | 36 | 63 |
FAB, French-American-British; MDS, myelodysplastic syndrome.
Refractory disease, relapse, or death from any cause.
Combination of idarubicin and cytarabine with or without mitoxantrone/thioguanine, or etoposide, cytarabine, and mitoxantrone with or without gemtuzumab or all-trans retinoic acid and arsenic trioxide (acute promyelocytic leukemia).